Qi Xiaolong, Li Jie, Caussy Cyrielle, Teng Gao-Jun, Loomba Rohit
Department of Radiology, Center of Portal Hypertension, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging and Interventional Radiology (Southeast University), Nanjing, China.
Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China; State Key Laboratory of Digital Medical Engineering, Nanjing, China.
Hepatology. 2024 May 8. doi: 10.1097/HEP.0000000000000913.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasingly recognized as a prevalent global burden. Type 2 diabetes mellitus (T2DM), another important metabolic disease, is considered a major contributor to the development of MASLD. MASLD and T2DM have a strong association with each other due to shared pathogenic mechanisms. The co-existence of the 2 diseases increases the risk of liver-related adverse outcomes and imposes a heavier burden on extrahepatic outcomes, representing a substantial public health issue. Effective assessment and management of T2DM combined with MASLD necessitate a multidisciplinary approach. The emergence of numerous RCTs has shed light on the treatment of T2DM combined with MASLD. This review uncovers the epidemiology of the intertwined T2DM and MASLD, offers insights into the evaluation of hepatic fibrosis in patients with T2DM, glucose monitoring in the MASLD population, and provides comprehensive co-management strategies for addressing both diseases.
代谢功能障碍相关脂肪性肝病（MASLD），以前称为非酒精性脂肪性肝病（NAFLD），日益被视为一种普遍的全球负担。2型糖尿病（T2DM）是另一种重要的代谢性疾病，被认为是MASLD发生发展的主要促成因素。由于共同的致病机制，MASLD和T2DM相互之间存在密切关联。这两种疾病的共存增加了肝脏相关不良结局的风险，并给肝外结局带来更沉重的负担，这是一个重大的公共卫生问题。对T2DM合并MASLD进行有效的评估和管理需要采取多学科方法。众多随机对照试验（RCT）的出现为T2DM合并MASLD的治疗提供了线索。本综述揭示了相互交织的T2DM和MASLD的流行病学，为T2DM患者肝纤维化的评估、MASLD人群的血糖监测提供了见解，并提供了针对这两种疾病的综合联合管理策略。
